BillionToOnevsMerck & Company

BLLN and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BLLN

BillionToOne, Inc.

$97.50

Value $4.6B

+1.24%
BLLN's page

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

BillionToOne (BLLN) has a market value of $4.6B and Merck & Company (MRK) $354B. Over the last year, with dividends, BLLN moved +8.3% and MRK +58.8%. The P/E is 100.3 for BLLN and 144.5 for MRK. Dividend yield: BLLN none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BLLN$4.6B

    MRK$354B

    MRK is 77 times BLLN

  • Revenue, 12 months

    BLLN$437M

    MRK$67.4B

    MRK is 154 times BLLN

  • Net income, 12 months

    BLLN$49M

    MRK$2.5B

    MRK is 50 times BLLN

  • Operating margin

    BLLN10.2%

    MRK–

  • ROIC

    BLLN7.9%

    MRK3.9%

    4.0 points apart

  • P/E

    BLLN100.3

    MRK144.5

    MRK is 1.4 times BLLN

  • Dividend yield

    BLLN0.0%

    MRK2.4%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BLLN+8.3%

MRK+58.8%

100150DecFebAprJunAugOct
Returns by period
PeriodBLLNWith dividendsMRKWith dividends
1 year since November 14, 2025+8.3%Price +8.3%+58.8%Price +54.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BLLNBillionToOneMRKMerck & Company

Valuation

BLLNMRK
Valuation
Price$97.50$143.37
Market value$4.6B$354B
Enterprise value (EV)$4.1B$399B
P/E100.3144.5
P/E, 5-year median–14.8
P/B8.17.9
EV/EBIT92.683.7
Free cash flow yield0.7%4.2%

Results and growth

BLLNMRK
Results and growth
Revenue, 12 months$437M$67.4B
Net income, 12 months$49M$2.5B
Free cash flow, 12 months$34M$14.7B
Earnings per share, 12 months$0.97$0.98
Revenue growth, year on year100.0%1.3%
Revenue growth a year, past+106.2%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

BLLNMRK
Margins and returns on capital
Gross margin71.4%71.8%
Operating margin10.2%–
Net margin11.3%3.6%
ROIC7.9%3.9%
ROE13.4%5.2%

Balance sheet

BLLNMRK
Balance sheet
Cash$562M$9.7B
Total debt$140M$53.8B
Net debt / EBITDA-9.25.7
Interest cover1,655.3×2.4×

Dividends and buybacks

BLLNMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BLLN or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, BillionToOne or Merck & Company?

By market value, Merck & Company ($354B) is about 76.9 times BillionToOne ($4.6B), at today's prices.

How did BLLN and MRK stock do over the last 1 years?

Since November 14, 2025, BLLN's price moved +8.3% and MRK's +54.3%. With dividends: BLLN +8.3% (+8.3% a year), MRK +58.8% (+58.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, BLLN or MRK?

The dividend yield at today's price is none for BillionToOne and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of BLLN and MRK?

At today's price, the P/E is 100.3 for BLLN and 144.5 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, BillionToOne or Merck & Company?

Over the last twelve months, the net margin was 11.3% for BillionToOne and 3.6% for Merck & Company, and the operating margin 10.2% and –. Revenue was $437M and $67.4B.

Which is the better investment, BillionToOne or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.